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Summary
Objective: To systematically review published randomized controlled trials (RCTs) evaluating pharmacological and non-pharmacological
therapies in patients with hand osteoarthritis (OA), with an emphasis on trial methodology.
Methods: RCTs published between 1966 and August 2004 were identiﬁed by searching several electronic data sources as well as by
searching reference lists. Details of study demographics, methodology, quality and outcomes were analyzed. A meta-analysis was planned, if
feasible.
Results: Thirty-one RCTs evaluating various pharmacological and non-pharmacological therapies in hand OA were analyzed in this
systematic review. When compared with hip and knee OA, there are surprisingly few published RCTs in hand OA. Generally, these RCTs are
of low quality. RCTs are weakened by a lack of consistent case deﬁnition and by a lack of standardized outcome assessments. The methods
used for randomization, blinding, and allocation concealment were rarely described. The number and location of symptomatic hand joints per
treatment group at baseline was usually not stated. The number and location of evaluated hand joints at the end of the study was also usually
not stated. A meta-analysis could not be performed since most of the treatments studied did not have more than one identical comparison to
allow pooling of the data.
Conclusion: It is apparent that hand OA is a more complex area in which to study the efﬁcacy of therapies when compared to hip and knee OA.
Consensus guidelines are urgently needed to help improve the design and conduct of RCTs in hand OA. Additional RCTs of high quality that
follow consensus recommendations are needed to evaluate the wide range of possible therapeutic options available for patients with hand OA.
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SocietyIntroduction
Osteoarthritis (OA) of the hand is a common problem that
has received relatively little attention when compared to OA
of the hip and knee. Data from the Framingham Study
revealed that in the age group of 71e100 years, the
prevalence of symptomatic hand OA was 26% in females
and 13% in males1. Compared to those without symptom-
atic hand OA, subjects with the disease had reduced
maximal grip strength and reported more difﬁculty in writing,
handling, or ﬁngering small objects1. Results from the
Framingham study, along with the results from other clinical
studies2e4, conﬁrm that hand OA is similar to other forms
and locations of OA, in that the end result is often pain and
stiffness, which can often result in functional limitation and
an impaired quality of life.
Despite the high prevalence of symptomatic hand OA,
there is a remarkable paucity of published clinical research
pertaining to the clinical impact, epidemiology, and therapy
1Sources of support: none. This work was presented by the
author at the OARSI World Congress of Osteoarthritis meeting in
December 2004 at Chicago, USA.
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Received 7 February 2005; revision accepted 13 February 2005.45of the condition. In terms of epidemiology, the following risk
factors are felt to be of etiologic importance: age, genetics,
gender, hormonal factors, obesity, and mechanical fac-
tors5,6.
Two systematic reviews evaluating randomized con-
trolled trials (RCTs) in hand OA have been published7,8.
These reviews analyzed trials published within the time
period of 1983 to 2000. The main ﬁndings of these two
reviews were that there are very few published RCTs
evaluating therapies in hand OA, and that these RCTs are
weakened by numerous methodological ﬂaws. The authors
also emphasized the great importance and urgent need for
developing consensus guidelines on how future RCTs in
hand OA should be done.
Objective
The objective of this paper is to systematically review all
published RCTs evaluating pharmacological and non-
pharmacological therapies in patients with hand OA, with
an emphasis on trial methodology. Only RCTs published
between 1966 and August 2004 were considered.
Criteria for inclusion
TYPES OF STUDIES
Only RCTs evaluating a therapeutic intervention in
subjects with hand OA are included in this systematic5
456 T. E. Towheed et al.: Systematic review of OA hand trialsreview. The trial report must have explicitly stated that
a randomized method of allocation to a treatment group was
employed. There were no language restrictions in the
electronic searches. Trials of any methodological quality
were included.
TYPES OF PARTICIPANTS
Adults with hand OA. Hand OA may have been deﬁned
by any method or by no method at all.
TYPES OF INTERVENTION
Any therapeutic intervention was considered. However,
RCTs evaluating surgical therapies were excluded.
TYPES OF OUTCOME MEASURES
Data pertaining to all outcomes presented in the trial
report were extracted. However, the greatest importance
was given to those outcomes currently recommended by
both Osteoarthritis Research Society International and
Outcome Measures in Arthritis Clinical Trials9,10. These
outcomes include pain, functional status, patient global
assessment, physician global assessment, radiological
progression, and health-related quality of life.
Criteria for exclusion
The following exclusion criteria were applied: (1) RCTs
evaluating surgical therapy, (2) RCTs presented in dupli-
cate, (3) non-English RCTs were included only if their
English abstracts contained sufﬁcient details pertaining to
trial methodology and outcomes, and (4) unpublished RCTs
were excluded.
Search strategy and study identiﬁcation
The following electronic data sources were systematically
searched: (1) MEDLINE (1966 to January week 2, 2004),
(2) PREMEDLINE (January week 2, 2004), (3) EMBASE
(1980 to January week 2, 2004, (4) Cochrane Central
Register of Controlled Trials (CCTR) (January 2004).
Reference lists of all retrieved articles were also manually
searched to identify additional potential trials. The initial
search was devised and carried out by a librarian scientist
(J. McGowan, MLS).
All searches were updated in August 2004. It is important
to note that the search strategy did not include the following:
(1) hand searching of conference proceedings, and (2)
personal communication with experts. The ﬂow chart sum-
marizing study identiﬁcation and retrieval is shown in Fig. 1.
The search strategy used in MEDLINE is shown below:
1. osteoarthritis/
2. (osteoarthritis or osteoarthrosis or degenerative
arthritis).tw.
3. 1 or 2
4. exp hand/
5. (hand$ or ﬁnger$ or wrist$ or digit$).tw,sh.
6. 4 or 5
7. 3 and 6
8. meta-analysis.pt,sh.
9. (meta-anal: or metaanal:).tw.10. (quantitativ: review: or quantitativ: overview:).tw.
11. (methodologic: review: or methodologic: overview:).tw.
12. (systematic: review: or systematic: overview).tw.
13. review.pt. and medline.tw.
14. or/8-13
15. clinical trial.pt.
16. randomized controlled trial.pt.
17. tu.fs.
18. dt.fs.
19. random$.tw.
20. (double adj blind$).tw.
21. placebo$.tw.
22. or/15-21
23. 7 and 14
24. 7 and 22
25. 23 or 24
A total of 31 RCTs were included in this systematic
review11e40 (Tables I and II). Twenty-two of the RCTs were
indexed in MEDLINE. An additional ﬁve RCTs were
identiﬁed from searching EMBASE. No additional trials
were identiﬁed by searching PREMEDLINE or the CCTR.
Four additional RCTs were identiﬁed by searching the
reference lists of the two previously published systematic
reviews of therapies of hand OA7,8.
Twenty-ﬁve reports evaluating therapies in hand OA were
excluded from this review since they did not meet one or
more of the stated inclusion criteria of this systematic
review41e65. Most of these reports were either not random-
ized or had an unclear randomization status (nZ 18
reports). Nine reports were non-English publications. Two
reports enrolled subjects with OA at multiple sites and did
not present efﬁcacy data speciﬁc to the hand. Three reports
did not clearly specify the site(s) of OA that was studied.
Two reports represented duplicate publications to those
already included in the review.
Methods
A data abstraction form, modiﬁed from the form used in
our previous Cochrane reviews evaluating OA therapies,
•   Citations considered potentially relevant (n=116)
•   Citations retrieved in full form for further
     evaluation (n=93) 
•   All citations identified and screened (n=519)
•   RCTs meeting inclusion criteria of systematic
    review (n=31) 
•   Citations excluded from systematic review (n=25)
    (see text)
 
Fig. 1. Flow chart of search strategy.
Table I
Published RCTs in OA of the hand
n Duration
(weeks)
Overall efﬁcacy
156 CPSO placebo
156 CSO placebo
ver NA* TrolamineO placebo
52 GAGPSO placebo
ver 6 (FiorinalZ ﬁpa) O placebo
ver 2 Short splintO long splintO no splint
28 All groups had less hand surgery
24 DPO placebo
ver 12 Uriel splintO others
4 MeclomenO placebo
0.012 TrolamineO placebo
2 IbuprofenO placebo
ver 12 Stinging nettle leafO placebo
9 CapsaicinO placebo
104 CSC naproxenO naproxen alone
260 GAGPSO placebo
Duration
(weeks)
Overall efﬁcacy
er 1.5 Equal
1 Equal
er 24 FolateCB12O (placeboZ folate)
3 LaserO placebo
12 Equal
10 YogaO no therapy
4 CapsaicinO placebo
12 JPEO info only
er 6 Equal
24 SpaO ibuprofen
3 Equal
0.7 Glove electrodeO carbon electrode
3 Equal
4 Equal
52 HQONSAIDC analgesic
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6Study (authors and year) Groups No.
randomized
No.
completed
Desig
Verbruggen et al., 200211 Chondroitin polysulphate (CPS) vs placebo 130 92 Parallel
Verbruggen et al., 200211 Chondroitin sulphate (CS) vs placebo 92 73 Parallel
Rothacker et al., 199412 Trolamine salicylate vs placebo 50 49 Cross-o
Pastinen et al., 198813 Glycosaminoglycan polysulphate (GAGPS) vs placebo 30 29 Parallel
Thorpe, 197014 Fiorinal vs ﬁpa vs placebo 10 9 Cross-o
Weiss et al., 200015 Short splint vs long splint vs no splint 26 26 Cross-o
Berggren et al., 200116 OT vs OTC textile splint vs OTC leather splint 33 33 Parallel
Reeves and Hassanein, 200017 Dextrose prolotherapy (DP) vs placebo 27 25 Parallel
Buurke et al., 199918 Uriel splint vs sporlastic splint vs gibortho splint 10 10 Cross-o
Seiler, 198319 Meclomen vs placebo 41 22 Parallel
Rothacker et al., 199820 Trolamine vs placebo 86 81 Parallel
Dreiser et al., 199321 Ibuprofen vs placebo 60 54 Parallel
Randall et al., 200022 Stinging nettle leaf vs placebo 27 24 Cross-o
Schnitzer et al., 199423 Capsaicin vs placebo 59 48 Parallel
Rovetta et al., 200424 CSC naproxen vs naproxen alone 24 24 Parallel
Verbruggen and Veys, 199325 GAGPS vs placebo 92 68 Parallel
*NAZ not available.
Table II
Published RCTs in OA of the hand
Study (authors and year) Groups No.
randomized
No.
completed
Design
Thiesce and Dougados, 199526 Topical diclofenac vs placebo 20 20 Cross-ov
Dougados and Nguyen, 199527 Topical niﬂumic acid vs placebo 186 186 Parallel
Flynn et al., 199428 Folate vs folateCB12 vs placebo 30 26 Cross-ov
Basford et al., 198729 Helium neon laser vs placebo 81 81 Parallel
Lisse et al., 200330 Rofecoxib vs naproxen 910 NA Parallel
Garﬁnkel et al., 199431 Yoga vs no therapy 26 25 Parallel
McCarthy and McCarty, 199232 Capsaicin vs placebo 14 14 Parallel
Stamm et al., 200233 Joint protection exercise (JPE) vs info only 40 40 Parallel
Swezey et al., 197934 Pressure glove vs control glove vs no glove 5 5 Cross-ov
Graber-Duvernay et al., 199735 Berthollet spa vs topical ibuprofen 116 107 Parallel
Zacher et al., 200136 Topical diclofenac vs oral ibuprofen 321 NA Parallel
Renklitepe et al., 199537 Tens electrode glove vs carbon electrode 36 NA Parallel
Talke, 198538 Topical etofenamate vs oral indomethacin NA NA Parallel
Caruso and Pietrogrande, 198739 SAMe vs naproxen vs placebo 51 NA Parallel
Punzi et al., 199640 Hydroxychloroquine (HQ) vs NSAIDC analgesics 15 15 Parallel
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mographics, methodology, quality, and outcomes66,67.
Study quality was evaluated by using the Jadad’s scoring
checklist68. The Jadad checklist comprises three questions
which evaluate different aspects of quality of an RCT: (1)
Was the study described as randomized?, (2) Was the
study described as double-blind?, and (3) Was there
a description of drop-outs and withdrawals?. A score of 1
is awarded for each question if this aspect of trial quality is
satisﬁed. An additional 1 point is awarded if the method of
randomization is described and is appropriate. An additional
1 point is awarded if the method of blinding is described and
is appropriate. One point is deducted if the method of
randomization is described and is inappropriate. One point
is also deducted if the method of blinding is described and is
inappropriate. The ﬁnal score ranges from 0 to 5, with
a higher score reﬂecting higher methodological quality.
Allocation concealment was speciﬁcally evaluated for
each RCT. Allocation concealment can be deﬁned as the
method used by the authors to prevent foreknowledge of
treatment group assignment in an RCT69. Allocation
concealment is a critical aspect of the quality of any RCT.
Studies that do not ensure appropriate allocation conceal-
ment are associated with inﬂated measures of treatment
effect and may be biased70.
A formal meta-analysis will be performed, if feasible. For
the quantitative outcomes, standardized mean differences
(SMD) will be used to pool across RCTs71. End of study
means and standard deviations will be used for calculation
of the SMDs. For dichotomous outcomes, relative risks
(RR) will be used to pool across RCTs. Heterogeneity will
be evaluated with a chi-square test. In order to calculate
clinical improvement, the number needed to treat (NNT) will
be calculated for dichotomous outcomes. Fixed effect
models will be used unless heterogeneity is statistically
signiﬁcant, in which case, random effects models will be
used. Where possible, data from an intention-to-treat
analysis will be extracted.
Results
OVERVIEW OF STUDY DEMOGRAPHICS
A total of 31 RCTs were analyzed in this systematic
review11e40 (Tables I and II). Two RCTs were published in
the 1970s, ﬁve were published in the 1980s, 14 were
published in the 1990s and 10 were published in the year
2000 or beyond. Twenty-four RCTs were available as
English full paper reports, four were non-English reports
with English abstracts, and three RCTs were only available
as English abstracts.
Symptom modifying therapy was evaluated in 26 RCTs,
whereas a structural modifying therapy was evaluated in
three RCTs11,25. Two RCTs evaluated both a symptom
modifying as well as a structural modifying therapy17,24. A
parallel, independent group study design was used in 24
RCTs and a cross-over design was used in seven RCTs.
The median number of subjects randomized per study was
only 38, with a range of 5 to 910. The median number of
subjects completing the trials was 27, with a range of 5 to
186. Thus, 71% of those randomized completed the RCT.
The median duration of the RCTs was 9.5 weeks, with
a range of 2 h to 260 weeks. Females were over
represented, in terms of the expected population preva-
lence of symptomatic hand OA1, since 81% of the subjects
randomized were females. The mean age of randomized
subjects in the RCTs was 61.5 years, with a range of 53 to69 years. Subjects had a mean duration of OA hand
symptoms of 6.2 years, with a range of 2 to 10 years.
Three RCTs had an open follow-up period after study
discontinuation. Twenty-one RCTs had a placebo group/
arm. Four RCTs were multi-center. The country of origin was
heterogeneous with the US having the greatest number of
RCTs (11), followed by France (4), Belgium (3), and Italy (3).
Eight RCTs had an oral non-steroidal anti-inﬂammatory
drug (NSAID) treatment group/arm. The individual NSAIDs
evaluated were: ibuprofen, naproxen, meclomen, rofecoxib
and indomethacin. Five RCTs had a topical NSAID
treatment group/arm. The individual topical NSAID prepa-
rations evaluated were: topical ibuprofen, topical etofena-
mate, topical diclofenac, and topical niﬂumic acid. Two
RCTs had a topical acetylsalicylic acid (ASA) group/arm.
Both studies evaluated topical trolamine salicylate in
comparison to a placebo. Four RCTs evaluated occupa-
tional therapy interventions. These included the following:
joint protection exercises, splints of various kinds and
technical accessories. Other active agents tested included
(number of trials): capsaicin cream (2), glycosoaminoglycan
polysulfate (GAGPS) (2) and chondroitin sulfate (2).
Several RCTs evaluated unconventional OA therapies
(number of trials): folate and cobalamin vitamin therapy
(1), laser therapy (1), yoga (1), dextrose prolotherapy (1),
pressure gradient gloves (1), spa therapy (1), stinging nettle
leaf (1), ﬁornal (1) and hydroxychloroquine (1).
FEATURES SPECIFIC TO HAND OA TRIALS
No consistent deﬁnition of hand OA was used in these
RCTs. Most trials (nZ 22) did not explicitly distinguish
between primary (idiopathic) and secondary OA. Seven
RCTs evaluated exclusively subjects with primary hand OA.
One RCT enrolled subjects with both primary and secondary
hand OA. Erosive hand OA which is considered to be
a subset of primary hand OA was studied exclusively in two
RCTs24,40. Only ﬁve RCTs used a validated hand OA clas-
siﬁcation scheme for study entry. These ﬁve studies used the
ACR classiﬁcation criteria72. Most often, hand OA was de-
ﬁned by the authors themselves with descriptions that lacked
sufﬁcient detail and precision (nZ 17 RCTs). Radiographs
were taken at baseline in 15 RCTs. However, detailed X-ray
criteria were explicitly stated in nine of these 15 RCTs.
The distribution of affected hand OA joints was quite
variable and was also inconsistently presented in the trial
reports. For example, eight RCTs did not specify which
joints were being evaluated in the hand. Four RCTs
evaluated exclusively subjects with 1st CMC OA15,16,18,22.
Ten RCTs evaluated subjects with interphalangeal proximal
interphalangeal (PIP) and/or distal interphalangeal (DIP)
OA, but not 1st CMC OA. Eight RCTs evaluated all three
joint areas (PIP, DIP and 1st CMC).
Only ﬁve RCTs presented detailed information pertaining
to the number and location of symptomatic hand joints per
treatment group at baseline. In four of these RCTs, only the
1st CMC joint was evaluated. This information is important
to include so that the reader can assess if the groups were
indeed evenly matched following randomization. Only 10
RCTs speciﬁed the number and location of evaluated hand
joints at the end of the study. Only six RCTs speciﬁed
a priori a hand joint site for efﬁcacy analysis.
Six RCTs did not specify whether one hand or both hands
were evaluated. Seven RCTs evaluated one hand only,
whereas, 17 RCTs evaluated both hands. Nine RCTs
speciﬁed a minimum entry criterion for symptoms and/or
objective ﬁndings, including speciﬁc X-ray criteria at baseline.
459Osteoarthritis and Cartilage Vol. 13, No. 6There was a lack of standardization of outcomes across
the 31 RCTs. Moreover, some outcome variables used in
these RCTs have not been validated in OA trials. Pain,
function, and patient global assessments were evaluated in
25, 23 and 13 RCTs, respectively. Physician global assess-
ments and health-related quality of life were evaluated in ﬁve
and two RCTs, respectively. Examples of outcome variables
used in these trials that have not been validated in OA trials
include joint swelling, joint tenderness, need for OA related
surgery, analgesic usage, sleep quality and range of motion.
A standardized, validated questionnaire (generic and/or
disease speciﬁc) was used for outcome assessment in 11
RCTs. This included the disease speciﬁc Australian
Canadian Osteoarthritis Hand Index (AUSCAN) question-
naire73 and the Dreiser’s Functional Index74.
FEATURES OF TRIAL QUALITY
Pre-randomization inclusion criteria were clearly speci-
ﬁed in 23 RCTs. Pre-randomization exclusion criteria were
clearly speciﬁed in 18 RCTs. Subjects were blinded in 20
RCTs and investigators were blinded in 21 RCTs. Only nine
RCTs were associated with a pharmaceutical company or
manufacturer. Four RCTs excluded subjects for protocol
violation. Six RCTs excluded subjects for adverse effects.
Twenty-three RCTS did not specify as to whether subjects
had prior exposure to the test agents. Eleven RCTs
controlled for supplementary analgesic usage or co-in-
tervention during the trial duration. Five RCTS presented
sample size calculations. Six RCTs provided a clearly
stated rationale for the chosen dosage of at least one active
agent. Six RCTs described the method of randomization.
Nine RCTs described the method of blinding. Nine RCTs
deﬁned a priori a main outcome variable. The success of
the blinding was not evaluated at the end of the study in any
of the included RCTs. Eleven RCTs presented sufﬁciently
detailed baseline data allowing the reader to ensure that the
groups were comparable at baseline. Fifteen RCTs used
appropriate statistical analyses. Examples of inappropriate
statistical analyses included: (1) using a parametric statis-
tical test for non-parametric data, (2) Stating that a margin-
ally insigniﬁcant statistical test was still statistically
‘‘signiﬁcant’’, (3) using a paired statistical test for indepen-
dent groups, (4) using multiple comparisons without
employing any statistical correction. For example, one
RCT evaluated several outcome variables, at separate time
points, for the right hand, left hand, both hands, and the
dominant hand. Thirteen RCTs either had no withdrawals or
used an intention-to-treat analysis. Only two RCTs ade-
quately described the method used to ensure allocation
concealment.
METHODOLOGICAL QUALITY BASED ON JADAD’S SCORES
The median Jadad score for the entire group of RCTs
was 3, with a range of 0 to 5. Twenty RCTs received a score
of 1 for being double-blinded. Twenty RCTs received
a score of 1 for providing an adequate description of
withdrawals and drop-outs. All RCTs were randomized as
per the inclusion criteria of the systematic review and
therefore all received a score of 1 for this criterion.
META-ANALYSIS
A formal meta-analysis could not be performed for
a number of reasons. First and most important, most of
the therapies studied did not have more than one identicalcomparison to allow pooling of the data. Second, studies
were too clinically diverse making a meta-analysis in-
appropriate. Third, generally these were low quality studies,
and this can adversely affect the validity of a meta-analysis.
Fourth, there was probable signiﬁcant publication bias, as
24 of the 31 RCTs reported a positive outcome (77%).
SUMMARY OF RESULTS OF THERAPIES
Due to the inherent methodological limitations in these
studies, it is difﬁcult to offer any reliable practical recom-
mendations for the choice of appropriate therapy in subjects
with clinically signiﬁcant hand OA (Tables I and II).
Clinicians will need to use their own judgment when
selecting appropriate treatments for symptomatic hand
OA. However, based on these 31 analyzed RCTs, one
can conclude that there is at least some evidence from
a published RCT for the efﬁcacy for the following therapies:
trolamine salicylate, GAGPS, ﬁornal and FIPA, splints for
1st CMC OA, occupational therapy, dextrose prolotherapy,
oral NSAIDs, stinging nettle leaf, topical capsaicin, vitamin
B12 with folate, yoga, and spa therapy. At least some
evidence also exists from a published RCT for structural
efﬁcacy in hand OA for the following therapies: chondroitin
sulfate, chondroitin polysulfate, and GAGPS.
Discussion
Results of this systematic review allows for a number of
general conclusions. First, there are surprisingly few
published RCTs evaluating the wide range of therapies
available for hand OA. Second, RCTs in hand OA are
weakened by a lack of consistent case deﬁnition and by
a lack of standardized outcome assessments. RCTs in
hand OA are also weak methodologically in other important
aspects. The most important issues relate to deﬁciencies in
allocation concealment, inadequate description of the
methods of randomization and blinding, failure to use
intention-to-treat analyses, inappropriate statistical analy-
ses, and failure to provide sample size calculations. Third,
a number of more speciﬁc methodological limitations
related to hand OA are also apparent. The number and
location of symptomatic joints per treatment group at
baseline was usually not stated. In addition, the number
and location of evaluated joints per treatment group at the
end of study was also usually not stated. RCTs were often
lacking important details regarding whether one or both
hands were evaluated, whether the 1st CMC joint and/or IP
joints were evaluated, and the selection a priori of both
a target joint site (1st CMC vs IP joints) and a principal
outcome measure for efﬁcacy evaluation.
Compared to knee and hip OA, hand OA is a more
complex area to evaluate therapy by using an RCT. The
increased complexity results from a number of unique
aspects. First, there are a large number of possibly affected
joints (10 joints per hand). This complicates the processes
of patient selection and outcome evaluation. Second, one
has to make an a priori decision as to whether the efﬁcacy
evaluation will focus on one hand, both hands, the dominant
hand or the most symptomatic hand. This is not necessarily
an easy distinction to make especially in light of the paucity
of published research. Third, it is not known whether 1st
CMC OA patients can be combined with patients having IP
OA. One published study by Spacek et al.75 suggests these
two groups should not be considered different during trials
assessing treatments for hand OA, when the primary
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clear if this also holds true when the primary outcome
measure is pain or a measure of radiological progression.
Fourth, it is believed by many that the natural history of
hand OA, in contrast to hip and knee OA, tends to be more
variable with spontaneous intermittent exacerbations and
improvements76,77. Moreover, pain, stiffness, and dexterity
also show circadian rhythms in subjects with hand OA76.
These are some of the issues that will need to be addressed
by the Osteoarthritis Research Society International
(OARSI) task force which is currently in the process of
developing Consensus Guidelines for the Design and
Conduct of trials in subjects with hand OA77.
Results of this systematic review are consistent with the
results obtained from the two previously published reviews
evaluating therapies for hand OA7,8. It is now widely agreed
that consensus guidelines are urgently needed as to how
future RCTs in hand OA ought to be done. A similar
approach has proven to be very successful in the past with
the development of the OARSI guidelines for the design
and conduct of trials in hip and knee OA9.
A number of limitations of this systematic review are
recognized. First, non-published trials were not systemat-
ically searched for or analyzed and this exclusion may have
resulted in a biased selection of trials which were more
likely to include positive trials. Second, conference pro-
ceedings were not manually searched. Third, non-English
publications were only included if they had an accompany-
ing English abstract which summarized sufﬁcient details of
the trial report.
A number of useful starting points for the development of
consensus guidelines should include the following publica-
tions: (1) the current OARSI guidelines for the design and
conduct of hip and knee OA RCTs9, (2) the OMERACT
guidelines outlining the choice of preferred outcome
variables in OA trials10, (3) the Consolidated Standards of
Reporting Trials (CONSORT) statement which outlines the
preferred method for reporting RCTs78, and (4) the recently
published Clinical Trials Registration Initiative which en-
courages the registration of future RCTs79.
Only a few published papers which discuss recommen-
dations for OA hand RCTs are currently available80e84 and
these would also represent useful starting points for the
development of consensus guidelines.
It is clear that additional RCTs of high quality that follow
consensus recommendations will be needed to evaluate
the wide range of possible treatment options in subjects
with hand OA.
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